SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NTII - Miscellaneous
An SI Board Since August 2001
Posts SubjectMarks Bans Symbol
1296 22 0 NTII
Emcee:  John McCarthy Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
11462005 - Effects of nicotinic and NMDA receptor channel blockers on intravenous coJohn McCarthy-2/12/2005
11452005 - Investing in a Cure By Charly Travers (TMFBreakerCharly) February 8, 20John McCarthy-2/8/2005
11442005 - Huntington's Disease link describing usage of Memantine .... hdlightJohn McCarthy-2/8/2005
11432004 - WallStreetReporter - Dated September 3, 2004 Interview With: Paul FreimJohn McCarthy-2/8/2005
11422005 - [AXYX] The Placebo Effect A MIND IS A terrible thing to waste, and so isJohn McCarthy-2/7/2005
1141Hi Zazarre - Sorry I did not get back to you sooner ..... (a) I own around 35,John McCarthy-2/7/2005
1140John, thanks for the articles on melatonin; in the past I have used it as a slelazarre-2/2/2005
11392005 - Melatonin #5 When melatonin gets on your nerves: its beneficial actions John McCarthy-2/1/2005
11382005 - Melatonin #4 Protective effect of melatonin on contractile activity and John McCarthy-2/1/2005
11372005 - Melatonin #3 Melatonin, metals, and gene expression: implications in agiJohn McCarthy-2/1/2005
11362005 - Melatonin #2 Retardation of brain aging by chronic treatment with melatoJohn McCarthy-2/1/2005
11352005 - Melatonin #1 Melatonin Relieves the Neural Oxidative Burden that ContribJohn McCarthy-2/1/2005
11342005 - Progress toward a more targeted treatment of Alzheimer's disease TuJohn McCarthy-2/1/2005
11332004 - Flurizan P1 Results Tuesday, July 20 2004 - 6:30 AM Myriad Genetics PresJohn McCarthy-1/31/2005
11322005 - CX717 Phase2 AD Cor FDA Ok's Business Editors/Health/Medical WritersJohn McCarthy-1/31/2005
11312005 - MEM Trial/Usage Update <b>Purpose:Gather Memantine Uses/Trials InfJohn McCarthy-1/30/2005
11302005 - Memantine & Carbofuran-induced oxidative stress 1: Toxicology. 2005 John McCarthy-1/29/2005
11292005 - Stuart Lipton 1: J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74. Related AJohn McCarthy-1/29/2005
11282005 - Memantine & Head Trauma in Rats 1: Neurosurg Rev. 2005 Jan 26; [EpuJohn McCarthy-1/29/2005
11272005 - Memaninte used for Catatonia <i>(2005 - neurosciencealliance)</John McCarthy-1/29/2005
11262005 - Carbofuran-induced oxidative stress in slow and fast skeletal muscles: prJohn McCarthy-1/25/2005
11252005 - Paradigm shift in NMDA receptor antagonist drug development: Molecular meJohn McCarthy-1/25/2005
11242005 - Antibody treatment partially reverses nerve damage in Alzheimer disease John McCarthy-1/21/2005
11232005 - NMDA glutamate but not dopamine antagonists blocks drug-induced reinstateJohn McCarthy-1/21/2005
11222005 - Symptomatic effect of donepezil, rivastigmine, galantamine and memantine John McCarthy-1/21/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News